Literature DB >> 29562154

Adverse Events Associated with Immune Checkpoint Blockade.

Michael A Postow1,2, Matthew D Hellmann1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29562154     DOI： 10.1056/NEJMc1801663

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

Review 1.  Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.

Authors:  Rachel A Bender Ignacio; Lilie L Lin; Lakshmi Rajdev; Elizabeth Chiao
Journal:  J Natl Compr Canc Netw       Date:  2018-08       Impact factor: 11.908

2.  Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Curtis R Chong; Vivian J Park; Bevin Cohen; Michael A Postow; Jedd D Wolchok; Mini Kamboj
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

3.  Scleroderma-like syndrome associated with pembrolizumab.

Authors:  Silvia Suárez-Díaz; Rubén Coto-Hernández; Carmen Yllera-Gutiérrez; Carlos Álvarez-Fernández; Luis Trapiella-Martínez; Luis Caminal-Montero
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

4.  Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota.

Authors:  Zishuo Ian Hu; Verena M Link; Djalma S Lima-Junior; Jérémie Delaleu; Nicolas Bouladoux; Seong-Ji Han; Nicholas Collins; Yasmine Belkaid
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-21       Impact factor: 12.779

Review 5.  Eosinophils and Lung Cancer: From Bench to Bedside.

Authors:  Anne Sibille; Jean-Louis Corhay; Renaud Louis; Vincent Ninane; Guy Jerusalem; Bernard Duysinx
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

6.  Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Authors:  Fernando C Santini; Hira Rizvi; Andrew J Plodkowski; Andy Ni; Mario E Lacouture; Maya Gambarin-Gelwan; Olivia Wilkins; Elizabeth Panora; Darragh F Halpenny; Niamh M Long; Mark G Kris; Charles M Rudin; Jamie E Chaft; Matthew D Hellmann
Journal:  Cancer Immunol Res       Date:  2018-07-10       Impact factor: 11.151

7.  A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.

Authors:  Dong Pan; Angela Y Hu; Scott J Antonia; Chuan-Yuan Li
Journal:  J Thorac Oncol       Date:  2020-12-08       Impact factor: 15.609

8.  Non-invasive Detection of Immunotherapy-Induced Adverse Events.

Authors:  Carolina A Ferreira; Pedram Heidari; Bahar Ataeinia; Nicoleta Sinevici; Meghan E Sise; Robert B Colvin; Eric Wehrenberg-Klee; Umar Mahmood
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

9.  Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.

Authors:  Marie Siwicki; Nicolas A Gort-Freitas; Marius Messemaker; Ruben Bill; Jeremy Gungabeesoon; Camilla Engblom; Rapolas Zilionis; Christopher Garris; Genevieve M Gerhard; Anna Kohl; Yunkang Lin; Angela E Zou; Chiara Cianciaruso; Evangelia Bolli; Christina Pfirschke; Yi-Jang Lin; Cecile Piot; John E Mindur; Nilesh Talele; Rainer H Kohler; Yoshiko Iwamoto; Mari Mino-Kenudson; Sara I Pai; Claudio deVito; Thibaud Koessler; Doron Merkler; Alexander Coukos; Alexandre Wicky; Montserrat Fraga; Christine Sempoux; Rakesh K Jain; Pierre-Yves Dietrich; Olivier Michielin; Ralph Weissleder; Allon M Klein; Mikael J Pittet
Journal:  Sci Immunol       Date:  2021-07-02

Review 10.  The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Authors:  Denis L Jardim; Aaron Goodman; Debora de Melo Gagliato; Razelle Kurzrock
Journal:  Cancer Cell       Date:  2020-10-29       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.